Xenon Pharmaceuticals Inc.
23
5
6
12
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 30/100
8.7%
2 terminated/withdrawn out of 23 trials
85.7%
-0.8% vs industry average
48%
11 trials in Phase 3/4
50%
6 of 12 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (23)
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
Role: lead
An Open-label Study of XEN1101 in Epilepsy
Role: lead
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
Role: lead
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures
Role: lead
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
Role: lead
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
Role: lead
An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)
Role: lead
An Open-Label Study of Azetukalner in Major Depressive Disorder
Role: lead
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
Role: lead
An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE
Role: lead
A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy
Role: lead
A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder
Role: lead
XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy
Role: lead
Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of XEN1101.
Role: lead
Single-dose Mass Balance Recovery and Metabolite Profile and Identification of 14C-XEN1101
Role: lead
Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of XEN901
Role: lead
A Safety, Tolerability, Efficacy and Exposure Study of XEN801 Topical Gel
Role: lead
Safety, Tolerability, Pharmacokinetics and Effects on Transcranial Magnetic Stimulation of Oral Doses of XEN1101
Role: lead
Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Patients With Primary/Inherited Erythromelalgia
Role: lead
A Crossover Study to Evaluate the Safety, Tolerability and Efficacy of XPF-002 in Subjects With Postherpetic Neuralgia (PHN)
Role: lead